Search tips
Search criteria 


Logo of gutGutView this articleSubmit a manuscriptReceive email alertsContact usBMJ
Gut. 1993; 34(2 Suppl): S119–S120.
PMCID: PMC1374032

Benelux multicentre trial of alpha interferon treatment for chronic hepatitis C: standard v high dose treatment monitored by biochemical and virological markers (interim analysis). Benelux Multicentre Trial Study Group.


In an interim analysis of the Benelux trial, no difference in alanine aminotransferase normalisation has been found between the high (6 million units) and standard (3 million units) doses of interferon alfa-2b during the first eight weeks of treatment. The probability of achieving normal alanine aminotransferase activity on at least two successive occasions during treatment is 65% for the standard dose and 73% for the higher dose. Measurement of plasma hepatitis C virus-RNA suggests that hepatitis C virus-RNA negativity after four weeks of treatment is a prerequisite for sustained response to interferon alfa-2b.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (253K), or click on a page image below to browse page by page.

Articles from Gut are provided here courtesy of BMJ Publishing Group